Sort by

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 645


Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.

Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A.

Lancet. 2017 Feb 4;389(10068):519-527. doi: 10.1016/S0140-6736(16)31594-X.


Adverse metaphase cytogenetics can be overcome by adding bortezomib and thalidomide to fractionated melphalan transplants.

Jethava Y, Mitchell A, Epstein J, Zangari M, Yaccoby S, Tian E, Waheed S, Khan R, Papanikolaou X, Grazziutti M, Cottler-Fox M, Petty N, Steward D, Panozzo S, Bailey C, Hoering A, Crowley J, Sawyer J, Morgan G, Barlogie B, van Rhee F.

Clin Cancer Res. 2016 Nov 3. pii: clincanres.2620.2015. [Epub ahead of print]


Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma.

Sawyer JR, Tian E, Shaughnessy JD Jr, Epstein J, Swanson CM, Stangeby C, Hale CL, Parr L, Lynn M, Sammartino G, Lukacs JL, Stein C, Bailey C, Zangari M, Davies FE, Van Rhee F, Barlogie B, Morgan GJ.

Leukemia. 2016 Nov 4. doi: 10.1038/leu.2016.253. [Epub ahead of print]


The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.

Pawlyn C, Kaiser MF, Heuck C, Melchor L, Wardell CP, Murison A, Chavan SS, Johnson DC, Begum DB, Dahir NM, Proszek PZ, Cairns DA, Boyle EM, Jones JR, Cook G, Drayson MT, Owen RG, Gregory WM, Jackson GH, Barlogie B, Davies FE, Walker BA, Morgan GJ.

Clin Cancer Res. 2016 Dec 1;22(23):5783-5794.


MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.

Qiang YW, Ye S, Chen Y, Buros AF, Edmonson R, van Rhee F, Barlogie B, Epstein J, Morgan GJ, Davies FE.

Blood. 2016 Dec 22;128(25):2919-2930. doi: 10.1182/blood-2016-03-706077.


Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma.

McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, van Rhee F, Zangari M, Heuck CJ, Petty N, Schinke C, Thanendrarajan S, Mitchell A, Hoering A, Barlogie B, Morgan GJ, Davies FE.

Clin Cancer Res. 2016 Oct 3. doi: 10.1158/1078-0432.CCR-16-0235. [Epub ahead of print]


Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma.

Jethava Y, Mitchell A, Zangari M, Waheed S, Schinke C, Thanendrarajan S, Sawyer J, Alapat D, Tian E, Stein C, Khan R, Heuck CJ, Petty N, Avery D, Steward D, Smith R, Bailey C, Epstein J, Yaccoby S, Hoering A, Crowley J, Morgan G, Barlogie B, van Rhee F.

Blood Cancer J. 2016 Sep 16;6:e471. doi: 10.1038/bcj.2016.85. No abstract available.


Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.

Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, Tytarenko R, Bauer MA, Meissner T, Deshpande S, Patel PH, Buzder T, Molnar G, Peterson EA, van Rhee F, Zangari M, Thanendrarajan S, Schinke C, Tian E, Epstein J, Barlogie B, Davies FE, Heuck CJ, Walker BA, Morgan GJ.

Blood. 2016 Sep 29;128(13):1735-44. doi: 10.1182/blood-2016-06-723007.


Differentiation stage of myeloma plasma cells: biological and clinical significance.

Paiva B, Puig N, Cedena MT, de Jong BG, Ruiz Y, Rapado I, Martinez-Lopez J, Cordon L, Alignani D, Delgado JA, van Zelm MC, Van Dongen JJ, Pascual M, Agirre X, Prosper F, Martín-Subero JI, Vidriales MB, Gutierrez NC, Hernandez MT, Oriol A, Echeveste MA, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Morgan GJ, Orfao A, Blade J, Mateos MV, Lahuerta JJ, San-Miguel JF.

Leukemia. 2017 Feb;31(2):382-392. doi: 10.1038/leu.2016.211.


Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma.

Jethava Y, Mitchell A, Zangari M, Waheed S, Schinke C, Thanendrarajan S, Sawyer J, Alapat D, Tian E, Stein C, Khan R, Heuck CJ, Petty N, Avery D, Steward D, Smith R, Bailey C, Epstein J, Yaccoby S, Hoering A, Crowley J, Morgan G, Barlogie B, van Rhee F.

Blood Cancer J. 2016 Jul 29;6(7):e453. doi: 10.1038/bcj.2016.64.


CA-125 secreting IgG kappa multiple myeloma.

Boota M, Schinke C, Ledoux S, Alapat D, Khan R, Barlogie B.

Am J Hematol. 2016 Oct;91(10):E457-8. doi: 10.1002/ajh.24456. No abstract available.


Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.

Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DL, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ.

Cancer Cell. 2016 May 9;29(5):639-52. doi: 10.1016/j.ccell.2016.03.026.


Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120).

Papanikolaou X, Rosenthal A, Dhodapkar M, Epstein J, Khan R, van Rhee F, Jethava Y, Waheed S, Zangari M, Hoering A, Crowley J, Alapat D, Davies F, Morgan G, Barlogie B.

Blood Cancer J. 2016 Mar 25;6:e410. doi: 10.1038/bcj.2016.19. No abstract available.


Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?

Thanendrarajan S, Davies FE, Morgan GJ, Schinke C, Mathur P, Heuck CJ, Zangari M, Epstein J, Yaccoby S, Weinhold N, Barlogie B, van Rhee F.

Immunotherapy. 2016;8(3):367-84. doi: 10.2217/imt.15.118. Review.


Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.

Paiva B, Corchete LA, Vidriales MB, Puig N, Maiso P, Rodriguez I, Alignani D, Burgos L, Sanchez ML, Barcena P, Echeveste MA, Hernandez MT, García-Sanz R, Ocio EM, Oriol A, Gironella M, Palomera L, De Arriba F, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Lahuerta JJ, Blade J, Orfao A, Mateos MV, San Miguel JF; Spanish Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Groups..

Blood. 2016 Apr 14;127(15):1896-906. doi: 10.1182/blood-2015-08-665679.


Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma.

Johnson DC, Weinhold N, Mitchell JS, Chen B, Kaiser M, Begum DB, Hillengass J, Bertsch U, Gregory WA, Cairns D, Jackson GH, Försti A, Nickel J, Hoffmann P, Nöethen MM, Stephens OW, Barlogie B, Davis FE, Hemminki K, Goldschmidt H, Houlston RS, Morgan GJ.

Nat Commun. 2016 Jan 8;7:10290. doi: 10.1038/ncomms10290.


Genetic factors influencing the risk of multiple myeloma bone disease.

Johnson DC, Weinhold N, Mitchell J, Chen B, Stephens OW, Försti A, Nickel J, Kaiser M, Gregory WA, Cairns D, Jackson GH, Hoffmann P, Noethen MM, Hillengass J, Bertsch U, Barlogie B, Davis FE, Hemminki K, Goldschmidt H, Houlston RS, Morgan GJ.

Leukemia. 2016 Apr;30(4):883-8. doi: 10.1038/leu.2015.342.


A common genetic variant in 19q13·3 is associated with outcome of multiple myeloma patients treated with Total Therapy 2 and 3.

Erickson SW, Stephens OW, Chavan SS, Epstein J, Barlogie B, Heuck CJ, Vangsted AJ.

Br J Haematol. 2016 Sep;174(6):991-3. doi: 10.1111/bjh.13830. No abstract available.


Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.

Bam R, Khan S, Ling W, Randal SS, Li X, Barlogie B, Edmondson R, Yaccoby S.

BMC Cancer. 2015 Nov 6;15:864. doi: 10.1186/s12885-015-1892-7.


Clinical value of molecular subtyping multiple myeloma using gene expression profiling.

Weinhold N, Heuck CJ, Rosenthal A, Thanendrarajan S, Stein CK, Van Rhee F, Zangari M, Hoering A, Tian E, Davies FE, Barlogie B, Morgan GJ.

Leukemia. 2016 Feb;30(2):423-30. doi: 10.1038/leu.2015.309.

Items per page

Supplemental Content

Loading ...
Support Center